Interim guideline for treatment options on cancer patients during SARS-CoV-2 pandemic
Cancer Research on Prevention and Treatment
; 47(4):227-234, 2020.
Article
in Chinese
| CAB Abstracts | ID: covidwho-1408605
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
In the current pandemic of SARS-Cov-2 (formally known as novel coronavirus disease 2019, COVID-19), the cancer treatment is particularly a challenge that must be overcome as soon as possible. Currently, the clinical data on the prevalence of SARS-Cov-2 in cancer patients is very limited, alone with constant evolving situations. To obtain existing evidence, we reviewed a wide range of medical literature and relevant websites including the National Health Commission of China. With the actual situation of Hubei Cancer Hospital, we formulated the interim guideline which was developed by all contributors from different disciplines after fully discussion, to provide the reference for treatment options on cancer patients, especially the cancer patients recovered from COVID-19 infection. This guideline highlighted the multidisciplinary team (MDT) diagnostic model, the assessment between risks and benefits prior to treatment, individualized service for patients' medical needs, and the acceptability in ethics and patients' socio-economic conditions.
Full text:
Available
Collection:
Databases of international organizations
Database:
CAB Abstracts
Language:
Chinese
Journal:
Cancer Research on Prevention and Treatment
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS